<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001573</url>
  </required_header>
  <id_info>
    <org_study_id>970087</org_study_id>
    <secondary_id>97-C-0087</secondary_id>
    <nct_id>NCT00001573</nct_id>
  </id_info>
  <brief_title>A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy</brief_title>
  <official_title>A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      A dose escalation scale consisting of 5 dosage levels is being used to determine the maximum&#xD;
      tolerated dose (MTD) of SU101. A minimum of 3 and a maximum of 6 patients will be enrolled at&#xD;
      each dose level. MTD is defined as the dose level immediately below that at which 2 or more&#xD;
      patients exhibit dose limiting toxicity.&#xD;
&#xD;
      Each treatment cycle is 21 days. Patients receive a 96 hour continuous IV infusion of SU101&#xD;
      on days 1-4.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SU101 is a member of a novel class of antineoplastic agents, platelet-derived growth factor&#xD;
      (PDGF) receptor inhibitors. Preclinical data suggests that SU101 might be an effective agent&#xD;
      against neuroglial tumors as well as a variety of sarcomas. A pediatric phase I trial of&#xD;
      SU101 in children with these malignancies will be conducted to find the maximum tolerated&#xD;
      dose of SU101 and define the toxicity profile of this agent. In addition, we will define the&#xD;
      pharmacokinetics of SU101 and its active metabolite SU0020 in pediatric patients and gather&#xD;
      preliminary information regarding response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <completion_date>May 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Glioma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU101</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically proven primary CNS malignancy, neuroblastoma or sarcoma that is refractory&#xD;
        to standard therapy or for which no standard therapy exists and disease can not be cured by&#xD;
        surgery.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Recovered from toxic affects of all prior therapy.&#xD;
&#xD;
        No investigational agent within past 2 weeks.&#xD;
&#xD;
        BIOLOGY THERAPY: Not specified.&#xD;
&#xD;
        CHEMOTHERAPY:&#xD;
&#xD;
        No myelosuppressive therapy within past 3 weeks.&#xD;
&#xD;
        No nitrosourea within past 6 weeks.&#xD;
&#xD;
        ENDOCRINE THERAPY: If receiving dexamethasone dose must be stable for at least 2 weeks.&#xD;
&#xD;
        RADIOTHERAPY: Not specified.&#xD;
&#xD;
        SURGERY: Not specified.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 3 to 21.&#xD;
&#xD;
        Performance status: ECOG 0-2.&#xD;
&#xD;
        Life expectancy: At least 8 weeks.&#xD;
&#xD;
        HEMATOPOIETIC:&#xD;
&#xD;
        AGC greater than 1500/mm(3).&#xD;
&#xD;
        Hemoglobin greater than or equal to 8.0 g/dL percent.&#xD;
&#xD;
        Platelet count greater than 100,000/mm(3).&#xD;
&#xD;
        For patients with bone marrow involvement or history of bone marrow transplantation or&#xD;
        craniospinal radiotherapy: AGC greater than 750/mm(3), Hemoglobin greater than 6.0 g/dL,&#xD;
        Platelet count greater than 50,000/mm(3).&#xD;
&#xD;
        HEPATIC:&#xD;
&#xD;
        SGOT, SGPT or alkaline phosphatase less than 3 times upper limit of normal.&#xD;
&#xD;
        Bilirubin no less than or equal to 1.5 times upper limit of normal.&#xD;
&#xD;
        RENAL:&#xD;
&#xD;
        Ages 3-5 Creatinine no greater than 0.8 mg/dL.&#xD;
&#xD;
        Ages 5-10 Creatinine no greater than 1.0 mg/dL.&#xD;
&#xD;
        Ages 10-15 Creatinine no greater than 1.2 mg/dL.&#xD;
&#xD;
        Ages 16-21 Creatinine no greater than 1.5 mg/dL.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        All patients or their legal guardians (if the patient is under 18 years old) must sign a&#xD;
        document of informed consent indicating their understanding of the investigational nature&#xD;
        and the risks of this study.&#xD;
&#xD;
        For patients with brain tumors who are over 18 years of age, a DPA should be signed.&#xD;
&#xD;
        Not pregnant or nursing.&#xD;
&#xD;
        Not allergic to etoposide.&#xD;
&#xD;
        No acute or chronic medical or psychiatric condition or laboratory abnormality that may&#xD;
        increase the risks associated with study participation/study drug administration or may&#xD;
        interfere with the interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Westermark B, Heldin CH, Nister M. Platelet-derived growth factor in human glioma. Glia. 1995 Nov;15(3):257-63. doi: 10.1002/glia.440150307.</citation>
    <PMID>8586462</PMID>
  </reference>
  <reference>
    <citation>Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest. 1990 Jul;86(1):131-40. doi: 10.1172/JCI114675.</citation>
    <PMID>2164040</PMID>
  </reference>
  <reference>
    <citation>Matsui T, Sano K, Tsukamoto T, Ito M, Takaishi T, Nakata H, Nakamura H, Chihara K. Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J Clin Invest. 1993 Sep;92(3):1153-60. doi: 10.1172/JCI116684.</citation>
    <PMID>8376577</PMID>
  </reference>
  <verification_date>February 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Glioma</keyword>
  <keyword>PDGF</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

